Home / Resource Library / Real‑world effectiveness and safety of ibrutinib in relapsed/refractory mantle cell lymphoma in Japan: post‑marketing surveillance
Real‑world effectiveness and safety of ibrutinib in relapsed/refractory mantle cell lymphoma in Japan: post‑marketing surveillance